Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background With smoking rates far exceeding the general population, methadone-maintained (MMT) opiate-dependent smokers experience high rates of tobacco-related health consequences. Previous treatment studies have used nicotine replacement and produced low quit rates. Methods We test, using a three-group randomized design, the efficacy of varenicline vs. placebo, in comparison with nicotine replacement therapy (NRT) that combines nicotine patch prescription plus ad libitum nicotine rescue, for smoking cessation. We recruited methadone-maintained smokers from nine treatment centers in southern New England and provided six months of treatment, and a minimal behavioral intervention at baseline (NCI's 5A's). Outcomes included carbon monoxide (CO) confirmed 7-day point smoking cessation prevalence at 6 months and self-reported change in mean cigarettes per day. Results The 315 participants had a mean age of 40, with 50% male and 79% non-Hispanic White, smoked an average of 19.6 (± 10.4) cigarettes / day, and had a mean daily methadone dose of 109 mg. Intent-to-treat analyses, with missing considered to be smoking, showed the rate of CO-confirmed 7-day abstinence at 6-months was 5.4% overall, with varenicline 3.7% compared to placebo 2.2%, and NRT 8.3% (p>.05). Adherence rates during the 7-days immediately prior to 6-month assessment were 34.2% in varenicline, 34.4% in placebo, and 48.8% in NRT. Between baseline and 6-months there was an overall self-reported mean reduction of 8.3 cigarettes / day. Conclusion Varenicline did not increase quit rates over placebo. Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 1×
“Overlapping neurobiological pathways in persons with dual opioid and nicotine dependence may affect withdrawal sensitivities and craving (Frosch et al., 2000; Pontieri et al., 1996).”
BackgroundNicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721 · cited 2×
“…cessation pharmacotherapies that have been tested in opioid dependent persons have far lower quit rates than those reported in trials of non-drug users (Hurt et al., 1994; Mooney et al., 2008; Okoli et al., 2010; Reid et al., 2008; Shoptaw et al., 2002; Stead et al., 2008; Stein et al., 2006b).”
BackgroundNicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · cited 1×
“First, there is data to suggest that longer treatment extends benefits without increasing risk of harm (Kornitzer et al., 1995; Tonstad et al., 2006; Williams et al., 2007).”
BackgroundGmel, G., & Rehm, J. (2004) · Contemporary Drug Problems · doi:10.1177/009145090403100304 · Cited by 466
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Tsukahara, H., Noda, K., & Saku, K. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0803 · Cited by 50 · cited 1×
“Two previous randomized trials compared varenicline to NRT (with brief weekly counseling sessions) in non-substance users and found no statistical difference between groups (Cahill et al., 2011; Tsukahara et al., 2010) with quit rates at 52 weeks in both studies of approximately 20%.”
Method
Cited by
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine replacement therapy versus control for smoking cessation
Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C., & Lancaster, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub5 · Cited by 697
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Sterling, L. H., Windle, S. B., Filion, K. B., Touma, L., & Eisenberg, M. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002849 · Cited by 70
Metadata
- Authors
- Stein, M. D., Caviness, C. M., Kurth, M. E., Audet, D., Olson, J., & Anderson, B. J.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 133
- Issue
- 2
- Pages
- 486-493
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2039579452
- Cited by
- 75
- References
- 11
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2013.07.005
- The paper
- Stein, M. D., Caviness, C. M., Kurth, M. E., Audet, D., Olson, J., & Anderson, B. J. (2013). Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2013.07.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.